Patient groups play lead role in research programs

Jay Tenenbaum wanted to do much more than help raise money for cancer research after his diagnosis for melanoma. He believes groups of patients like himself can advance new therapeutics that can save their lives. The multimillionaire created CollabRx with $2 million of his own money and is raising $3 million more. And Tenenbaum is hoping to create a group of "virtual" biotechs that can advance new research into life-saving therapies.

Patient-supported research efforts like his are having a real impact on the drug discovery arena, the Wall Street Journal reports. The Myelin Repair Foundation has provided $13 million to fund a team of researchers who will unveil their top two prospects to drug developers later this year. And the Cystic Fibrosis Foundation has supplied $75 million to advance a drug that has shown promise in clinical trials.

- read the article from the Wall Street Journal

Suggested Articles

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.